TNF and inflammatory bowel disease: Given that histamine currently demonstrates more proinflammatory rather than anti-inflammatory effects on the gut in IBD, the use of anti-TNF therapy (in particular, IFX) in patients with CD and UC may be accompanied by additional risks of inflammation.